Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT

Journal of Acquired Immune Deficiency Syndromes

Volumn 75, Issue 3, 2017, Pages 271-279

  Sivay, Mariya V ^a   Li, Maoji ^b   Piwowar Manning, Estelle ^a   Zhang, Yinfeng ^a   Hudelson, Sarah E ^a   Marzinke, Mark A ^a   Amico, Rivet K ^c   Redd, Andrew ^a,d   Hendrix, Craig W ^a   Anderson, Peter L ^e   Bokoch, Kevin ^f   Bekker, Linda Gail ^g   Van Griensven, Frits ^h   Mannheimer, Sharon ^i,j   Hughes, James P ^k   Grant, Robert ^l   Eshleman, Susan H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Howard Hughes Medical Institute   (United States)

^j Mailman School of Public Health   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

antiretroviral drugs; emtricitabine; HIV seroconverter; pre exposure prophylaxis; resistance; tenofovir

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACUTE HIV INFECTION; ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; FEMALE; FOLLOW UP; HIV RAPID TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; NEXT GENERATION SEQUENCING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEROCONVERSION; TRANSGENDER; TREATMENT DURATION; VIRAL LOAD TESTING; ANTIVIRAL RESISTANCE; BLOOD; DRUG EFFECTS; HIV SEROPOSITIVITY; PREDICTIVE VALUE; SOUTH AFRICA; THAILAND;

ADULT; ANTI-HIV AGENTS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, VIRAL; EMTRICITABINE, TENOFOVIR DISOPROXIL FUMARATE DRUG COMBINATION; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; PRE-EXPOSURE PROPHYLAXIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SOUTH AFRICA; THAILAND;

EID: 85015917451     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001374     Document Type: Article

References (27)

1. U. S. Food and Drug Administration. FDA-Approved HIV Medicines. 2016; Available at: https://aidsinfo. nih. gov/education-materials/factsheets/ 21/58/fda-approved-hiv-medicines. Accessed November 1, 2016.
2. Mugwanya KK, Baeten JM. Safety of oral tenofovir disoproxil fumaratebased pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf. 2016;15:265-273.
3. Spinner CD, Boesecke C, Zink A, et al. HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151-158.
4. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30: 1973-1983.
5. U. S. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at: https://wayback. Archive-it. org/7993/20170112032741/http://www. fda. gov/ NewsEvents/Newsroom/PressAnnouncements/ucm312210. htm. Accessed November 1, 2016.
6. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015. Available at: http://www. who. int/hiv/pub/guidelines/earlyrelease-arv/en/. Accessed November 12, 2016.
7. Center for Diseases Control. New guidelines recommend daily HIV prevention pill for those at substantial risk. 2014; 67. Available at: http:// www. cdc. gov/nchhstp/newsroom/2014/PrEP-Guidelines-Press-Release. html. Accessed November 1, 2016.
8. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
9. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
10. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411-422.
11. van der Straten A, Stadler J, Luecke E, et al. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: The VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc. 2014;17(3 suppl 2):19146.
12. Parikh UM, Mellors JW. Should we fear resistance from tenofovir/ emtricitabine preexposure prophylaxis Curr Opin HIV AIDS. 2016;11: 49-55.
13. Bekker LG, Hughes J, Amico KR, et al. HPTN 067/ADAPT background and methods and Cape Town results. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. Asbtract 978LB.
14. Mannheimer SB, Hirsch-Moverman Y, Loquere A, et al. Feasibility of intermittent PrEP among US MSM: data from the harlem site. Paper presented at: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 19-22, 2015; Vancouver, Canada. Abstract MOAC0305LB.
15. Holtz TH, Chitwarakorn A, Curlin ME, et al. A comparison of daily and nondaily preexposure prophylaxis dosing in Thai men who have sex with men, Bangkok. Paper presented at: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 19-22, 2015; Vancouver, Canada. Abstract MOAC0306LB.
16. Eshleman SH, Hudelson SE, Redd AD, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention trials network 052 trial. J Infect Dis. 2011;204:1918-1926.
17. Stanford University. HIV drug resistance database. 2016; Available at: https://hivdb. stanford. edu. Accessed November 3, 2016.
18. Louissaint NA, Cao YJ, Skipper PL, et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses. 2013; 29:1443-1450.
19. Bushman LR, Kiser JJ, Rower JE, et al. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390-401.
20. Hendrix CW, Andrade A, Bumpus NN, et al. Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016;32:32-43.
21. Zheng JH, Rower C, McAllister K, et al. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabinetriphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016;122:16-20.
22. Guanira JV, Leigler T, Kallas E, et al. Streamlining HIV testing for HIV preexposure prophylaxis. J Clin Microbiol. 2015;53:179-183.
23. Curtis KA, Kennedy MS, Luckay A, et al. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis. J Acquir Immune Defic Syndr. 2011;57:355-362.
24. Donnell D, Ramos EM, Baeten J, et al. The effect of oral pre-exposure prophylaxis on the progression of HIV-1 seroconversion. Paper presented at: HIV Research for Prevention; October 17-21, 2016; Chicago, IL. Abstract OA03. 01.
25. Laeyendecker O, Redd AD, Nason M, et al. Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis. J Infect Dis. 2015;212:754-759.
26. Grant RM, Liegler T, Defechereux P, et al. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015;29:331-337.
27. Brookmeyer R, Laeyendecker O, Donnell D, et al. Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr. 2013;63(suppl 2):S233-S239.